Healthcare
Forian Inc.(FORA)
Live Price
Offline$2.68
+0.75% today
1Y Change
-32.32%
Window
Jun 25, 2025 โ Jun 19, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +50.1%
- EPS Growth
- +23.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Forian Inc. (FORA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $2.68 and down 32.3% across the available one-year price window (Jun 25, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of +50.1%, EPS growth of +23.0%, a dividend yield of 0.0%. What stands out right now is revenue +50.1%, EPS +23.0%, free cash flow +920.6% with operating margin -8.2% and ROIC -8.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FORA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+50.1% vs +7.6% peer median
Operating Margin
Below sector median
-8.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +50.1% and EPS at +23.0%, with operating margin around -8.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -5.0% | -3.2% | +0.0% |
2026 Mar 27, 2026 | -500.0% | +1.0% | -0.3% | -2.4% |
2025 Nov 14, 2025 | +100.0% | -2.0% | +0.0% | +0.7% |
Benchmark Edge
FORA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FORA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FORA Max Drawdown
-44.07%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FORA and SPY.
Company Overview
Forian Inc.
NASDAQ Capital Market
Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides clients with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain; and STEMS, a seed-to-sale tracking module, to provide cannabis program management solution to cannabis regulatory agencies. In addition, the company offers security monitoring and web marketing services. The company is headquartered in Newtown, Pennsylvania.
- Leadership
- Max C. Wygod
- IPO Date
- Mar 3, 2021
- Employees
- 47
- Street Address
- 41 University Drive
- Mailing
- Newtown, PA, 18940
- Region
- Newtown, PA, US
- Reporting Currency
- USD
- Investor Line
- 267 225 6263
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.2
- Price/Book
- 2.2
Growth
- Revenue
- +50.1%
- EPS
- +23.0%
- Free Cash Flow
- +920.6%
Profitability
- Gross Margin
- 52.5%
- Operating Margin
- -8.2%
- Net Margin
- -9.5%
- ROE
- -9.4%
- ROIC
- -8.3%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 2.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.